SEC Form 4 · accession 0000899243-15-005202
ImmunoCellular Therapeutics, Ltd. · IMUC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark A Schlossberg
Director
Period of report
Sep 18, 2015
Accepted (ET)
Sep 22, 2015 · 4:57 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000822411
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Rt to Buy)F1 | $0.47 | Sep 18, 2015 | A | 40,000 | A | — | Sep 17, 2022 | Common Stock | 40,000 | 40,000 | D |
Explanation of responses
- F1The option shall vest in a series of 16 equal consecutive quarterly installments over a four year period following the September 18, 2015 grant date.